Selecta Biosciences Inc (NASDAQ:SELB) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 633,900 shares, a drop of 8.2% from the September 30th total of 690,200 shares. Currently, 2.1% of the shares of the stock are sold short. Based on an average daily volume of 133,400 shares, the short-interest ratio is presently 4.8 days.
SELB opened at $1.41 on Tuesday. The company has a market cap of $66.51 million, a price-to-earnings ratio of -0.48 and a beta of 1.11. Selecta Biosciences has a 52-week low of $1.28 and a 52-week high of $6.25. The firm’s fifty day simple moving average is $1.52 and its two-hundred day simple moving average is $1.84.
Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. As a group, sell-side analysts expect that Selecta Biosciences will post -1.23 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Selecta Biosciences by 7.3% in the second quarter. Vanguard Group Inc. now owns 1,620,305 shares of the company’s stock worth $2,901,000 after buying an additional 109,806 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Selecta Biosciences by 98.4% in the second quarter. Renaissance Technologies LLC now owns 471,500 shares of the company’s stock worth $844,000 after buying an additional 233,800 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Selecta Biosciences in the second quarter worth about $275,000. Jane Street Group LLC purchased a new position in shares of Selecta Biosciences in the second quarter worth about $195,000. Finally, Morgan Stanley lifted its stake in shares of Selecta Biosciences by 582.4% in the second quarter. Morgan Stanley now owns 63,784 shares of the company’s stock worth $114,000 after buying an additional 54,437 shares in the last quarter. 42.01% of the stock is currently owned by hedge funds and other institutional investors.
SELB has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price objective on shares of Selecta Biosciences in a report on Friday, November 8th. ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $6.00 price objective on shares of Selecta Biosciences in a report on Friday, November 8th. Finally, Mizuho reaffirmed a “buy” rating and set a $4.00 price objective on shares of Selecta Biosciences in a report on Sunday, August 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Selecta Biosciences presently has a consensus rating of “Buy” and a consensus price target of $6.80.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Featured Story: What is a Real Estate Investment Trust (REIT)?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.